Recruiting
Phase 2

TXA with HA

Sponsor:

University of Wisconsin, Madison

Code:

NCT06665594

Conditions

Facial Filler Injections

Hyaluronic Acid

Tranexamic Acid

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Hyaluronic Acid (HA)

Tranexamic Acid (TXA)

Saline (placebo)

Study Details

Brief summary:

The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is:

  • Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection?

Participants will receive the study medication along with the standard facial filler injection and complete surveys.

Conditions

Facial Filler Injections

Hyaluronic Acid

Tranexamic Acid

Study ID

NCT06665594

Start date

Dec 5, 2025

Status verified date

Jul, 2026

Completion date

Nov, 2026

Anticipated

Primary completion date

Nov, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age equal to or greater than 18 but less than or equal to 89 years.
  • Participants interested in facial filler (HA) injection.
  • English speaking.

Exclusion Criteria:

  • Minors or under the age of 18
  • Participant over the age of 89
  • Pregnant or breast-feeding women
  • Individuals unable to give consent due to another condition such as impaired decision-making capacity.
  • Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis
  • Participants undergoing unilateral facial filler (HA) injection
  • Participants with history of hypersensitivity to TXA or any of the other ingredients
  • Participants that are on current therapeutic anticoagulation therapy and aspirin use
  • Participants with stage 2 or greater renal failure
  • Participants on hemodialysis or peritoneal dialysis
  • History of diabetes or seizures
  • Current tobacco smokers
  • Acquired defective color vision

Study Design

Enrollment

40 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Facial Filler Injection

TXA plus HA injection in half of face, saline plus HA injection on other half of face

Interventions

Hyaluronic Acid (HA)

Injectable gel

Tranexamic Acid (TXA)

Injection of TXA

Saline (placebo)

Injection of saline

Primary outcome measure

  • Intensity of bruising on TXA + HA half of face [ Time Frame: Post-procedure day 7 ]
  • Intensity of bruising on saline + HA half of face [ Time Frame: Post-procedure day 7 ]
  • Duration of bruising on TXA + HA half of face [ Time Frame: Post-procedure day 7 ]
  • Duration of bruising on saline + HA half of face [ Time Frame: Post-procedure day 7 ]

Central Contacts and Locations

Central contacts

Daniel Cho, MD, PhD

608-263-6330chod@surgery.wisc.edu

Locations

University of Wisconsin - Madison

Recruiting

Madison, Wisconsin, United States, 53705

Contacts

Daniel Cho, MD, PhD

608-263-7502chod@surgery.wisc.edu

Principal Investigator:

Daniel Y Cho, MD, PhD

More Information

Sponsor

University of Wisconsin, Madison

Last update posted

Jul 23, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Wisconsin, Madison on 2026-07-23.